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Abstract
Objectives: Rapid eye movement sleep behavior disorder (RBD) patients have
a high risk of developing a Parkinsonian disorder, offering an opportunity for
neuroprotective intervention. Predicting near-term conversion, however,
remains a challenge. Dopamine transporter imaging, while informative, is
expensive and not widely available. Here, we investigate the utility of suscepti-
bility-weighted MRI (SWI) to detect abnormalities of the substantia nigra in
RBD, and explore their association with striatal dopaminergic deficits. Methods:
SWI of the substantia nigra was performed in 46 RBD patients, 27 Parkinson’s
patients, and 32 control subjects. Dorsal nigral hyperintensity (DNH) was
scored by two blinded raters, and separately quantified using a semiautomated
process. Forty-two RBD patients were also imaged with 123I-ioflupane single-
photon emission computed tomography (DaT SPECT/CT). Results: Consensus
visual DNH classification was possible in 87% of participants. 27.5% of RBD
patients had lost DNH, compared with 7.7% of control subjects and 96% of
Parkinson’s patients. RBD patients lacking DNH had significantly lower puta-
men dopaminergic SPECT/CT activity compared to RBD patients with DNH
present (specific uptake ratios 1.89 vs. 2.33, P = 0.002). The mean quantified
DNH signal intensity declined in a stepwise pattern, with RBD patients having
lower intensity than controls (0.837 vs. 0.877, P = 0.01) but higher than PD
patients (0.837 vs. 0.765, P < 0.001). Interpretation: Over one quarter of RBD
patients have abnormal substantia nigra SWI reminiscent of Parkinson’s, which
is associated with a greater dopaminergic deficit. This modality may help enrich
neuroprotective trials with early converters.
26 ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
Introduction
Parkinson’s disease presents clinically at a time when sub-
stantial neurodegeneration in the nigrostriatal system has
already occurred.1 Identifying early disease during the pro-
dromal phase is therefore important in maximizing the
potential of future neuroprotective interventions. Patients
with rapid eye movement sleep behavior disorder (RBD)
have a long-term risk exceeding 80% of developing Parkin-
son’s disease or a related alpha-synucleinopathy, and there-
fore, present an opportunity to target the prodromal
period.2 Due to the long and variable latency, however,
near-term phenoconversion rates are considerably lower,
with around 33% of RBD patients on average developing a
synucleinopathy within 5 years of RBD diagnosis.3 Identifi-
cation of these highest-risk patients using disease-specific
markers of neurodegeneration would aid individual prog-
nosis and increase the feasibility of clinical trials aimed at
delaying or preventing conversion to motor disease.4
Susceptibility-weighted MRI has emerged recently as a
promising tool for evaluating the integrity of the substantia
nigra.5 In healthy subjects, an area of signal hyperintensity is
seen in the dorsal nigra corresponding to nigrosome 1, a
nucleus affected early by synuclein-mediated degeneration.6
This dorsal nigral hyperintensity (DNH) is lost in around
98% of patients with Parkinson’s disease.5 Three recent
studies have indicated that the DNH is absent in a smaller
proportion of RBD patients,7–9 suggesting a potential role in
the characterization of prodromal disease progression.
Most studies examining the DNH have used subjective,
binary ratings to measure its presence or absence,10,11 but
the value of SWI imaging as a prodromal progression mar-
ker could potentially be enhanced by an objective method of
quantifying the DNH signal that reflected the gradually pro-
gressive degeneration that occurs in the substantia nigra.
This multimodal neuroimaging study was designed to
evaluate the DNH using SWI in a large cohort of
polysomnographically proven RBD patients, alongside
healthy control subjects and patients with Parkinson’s dis-
ease. By performing MRI and dopamine transporter SPECT/
CT in parallel, we sought to investigate the relationship
between DNH loss and striatal dopaminergic decline in the
prodromal phase. We further aimed to develop a semiauto-
mated method of measuring the DNH signal that could
objectively quantify the differences between RBD patients,
PD patients, and healthy control subjects.
Methods
Participants
The study was approved by the local ethical committee and
written, informed consent was obtained from all participants.
A total of 105 participants were recruited prospectively for the
study as volunteers from an existing cohort, described else-
where.12 The initial study population comprised 46 patients
with RBD, 27 patients with Parkinson’s disease, and 32
healthy control subjects. RBD was diagnosed by polysomnog-
raphy according to the International Classification of Sleep
Disorders criteria.13 In all cases, RBD was considered idio-
pathic, not secondary to another neurological disorder or
medication. RBD patients with evidence of dementia or
motor parkinsonism were not eligible for inclusion.
All participants underwent imaging with susceptibility-
weighted MRI and 42 RBD patients were scanned in par-
allel with 123I-ioflupane SPECT/CT.
Clinical examination
Participants were examined on the day of imaging by a
neurologist using the Movement Disorders Society Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS) part III.14
Other clinical motor and nonmotor markers of prodromal
parkinsonism were assessed in RBD patients using standard
rating scales, described elsewhere.12 The probability of pro-
dromal PD was calculated for each RBD patient using the
Movement Disorders Society research criteria.15
MRI acquisition and processing
T2*-weighted images were acquired on a 3T Siemens Trio
(Erlangen, Germany) using a 12-channel receive-only
head coil (gradient-recalled echo, 256 matrix, voxel size
= 0.86 9 0.86 9 1.50 mm3, TE/TR = 20 msec/27 msec,
flip angle = 15°; 5 min). Axial slices were oriented paral-
lel to the plane between the anterior and posterior com-
missures. Phase images were high-pass filtered using a
50 9 50 window in Fourier space to remove macroscopic
phase artifacts. This window size was selected empirically
to suppress artifacts in the midbrain caused by nearby
aerated structures. Paramagnetic phase components only
were taken to the fourth power and then multiplied with
the magnitude images to give the final susceptibility-
weighted images.
T1-weighted structural MRI was acquired to facilitate
the registration of SWI images to standard space, with
acquisition parameters as follows: 3T Siemens Trio
(Erlangen, Germany), 12-channel receive-only head coil,
MPRAGE, TE/TR/TI = 4.7 msec/2040 msec/900 ms; 192
axial slices; isotropic voxel size 1 mm3; 6 min.
SPECT/CT acquisition and analysis
The protocol used for SPECT/CT acquisition and image
processing was performed as previously described16.
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SPECT/CT data were analyzed using BRASS software
(HERMES Medical Solutions AB, Stockholm). Recon-
structed images for each patient were registered to a stan-
dard template including regions of interest (ROIs) for the
caudate and putamen on each side. Uptake ratios were
calculated for these ROIs using a standard reference
region. Additionally, each SPECT/CT scan was reported
descriptively in a standard clinical manner by an experi-
enced nuclear medicine radiologist (KMB) who was
blinded to all clinical and MRI data except for the partici-
pants’ age, gender, and presence of RBD. The descriptive
reports were categorized as either normal, abnormal, or
borderline.
MRI analysis
For the subjective ratings of the dorsal nigral hyperinten-
sity (DNH), SWI images from all 105 subjects were first
anonymized and compiled into a single 4D file in random
order by an investigator independent from the two raters.
Assessments were then performed independently by two
separate raters blinded to all clinical details including sub-
ject status (i.e., control, PD, or RBD), using a method
based on that described by Schwarz et al.10 Rater 1 was a
clinical neurologist with expertize in neuroimaging. Rater
2 was a research scientist specializing in brain MRI analy-
sis. Briefly: for each subject the DNH was scored as pre-
sent, absent or uncertain for the left and right substantia
nigra, respectively (Fig. 1A and B). Using these data the
scans were classified into two categories as follows: (1)
bilateral presence of the DNH, or unilateral presence with
the contralateral side uncertain, was considered normal
and is referred to as “DNH present;” (2) definite absence
of the DNH unilaterally or bilaterally was considered
abnormal and is referred to as “DNH absent.” In cases
where one rater classed the DNH as uncertain bilaterally
and the other rater gave a definite classification, the defi-
nite classification was used. Cases where both raters con-
sidered the images uncertain bilaterally were classed as
“nondiagnostic.” Where there was disagreement in out-
come between the two raters and one rater’s scoring
included “uncertain” for one side, a consensus rating was
sought by overruling the uncertain score (e.g., if left/right
was scored by one rater as “present/absent” [i.e., abnor-
mal] and by the other rater as “present/uncertain” [i.e.,
normal], the final rating used would be “present/absent”).
For the quantification of DNH signal, SWI images of
all participants were first nonlinearly registered to Mon-
treal Neurological Institute (MNI) standard space via T1-
weighted images. Registered SWI images were then nor-
malized to the background image intensity for each indi-
vidual by dividing the whole image by the mean intensity
of a region of interest in the brainstem parenchyma
remote from the substantia nigra (Fig. S1). A single,
study-specific template image was created in MNI space
using the mean values from the 32 healthy control sub-
jects to determine the normal average location of the
DNH (Fig. 1C). Using this template as a guide, a single,
standard space region of interest was drawn manually in
the area of the DNH on each side (Fig. 1D). The mean
intensity within this template nigrosome ROI was then
extracted from each individual subject’s normalized, stan-
dard space images. Values presented are the mean of left
and right DNH ROIs for each subject.
Statistical methods
Pairwise comparisons between groups were performed
using a chi-square test for dichotomized variables, and an
independent samples t-test for continuous variables.
Comparison between contralateral and ipsilateral values
within RBD patients was performed using a paired sam-
ples t-test. Correlations were calculated as Pearson coeffi-
cients. All statistical analyses were performed using SPSS
(IBM) version 25.
Results
Visual DNH assessment
Table 1 shows a breakdown of all subjects included in the
initial study population. Eight of 105 participants (four
RBDs, two PDs, and two controls) had SWI images that
were of inadequate quality for DNH assessment due to
image artifacts, and were excluded from all analyses. Base-
line demographic and clinical variables for the 97
included participants are shown in Table 2.
One included scan was considered nondiagnostic by
both raters in visual assessment of the DNH. Of the
remaining 96 scans, there was concordance between the
two raters in 89 (93%). In the seven scans in which there
was initial disagreement, a consensus rating was achieved
in two, leaving five cases that could not be resolved.
These five cases with inter-rater disagreement comprised
four control subjects and one RBD patient. The results of
visual DNH assessments for the 91 subjects with consen-
sus ratings are shown in Table 3.
Excellent discrimination accuracy was observed between
healthy controls and patients with Parkinson’s disease,
with the absence of DNH achieving a sensitivity of 96%,
specificity of 92%, positive predictive value of 92% and
negative predictive value of 96%. Among RBD patients
with rateable images, 11 of 40 (27.5%) had absence of the
DNH, while 29 (72.5%) had DNH present. The rate of
DNH absence in RBD patients was significantly higher
than controls (27.5% vs. 7.7%, P = 0.048) and
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significantly lower than PD patients (27.5% vs. 96.0%,
P < 0.001).
Unilateral abnormalities were more common in RBD
than PD patients, perhaps suggesting an intermediate pat-
tern of abnormality. Of the 11 RBD patients with DNH
absence, seven (64%) had retained DNH presence on one
side, whereas in PD patients with DNH absence, only 2
of 24 cases (8%) had unilateral DNH presence.
Association of DNH loss with prodromal
markers in RBD
Table 4 shows the scores across a range of prodromal
markers in RBD patients, grouped according to the pres-
ence or absence of DNH. Among individual markers,
none were more severely affected in RBD patients who
had lost DNH. However, when markers were combined
using the MDS research criteria for prodromal Parkin-
son’s disease, RBD patients with DNH absence had a sig-
nificantly higher probability of prodromal Parkinson’s
than those with DNH presence, suggesting that DNH loss
in RBD is associated with an increased risk of future
Parkinson’s disease.
Comparison of SWI and DaT SPECT/CT
imaging
Of the 42 RBD patients with parallel SWI and DaT
SPECT/CT imaging, 36 had diagnostic SWI imaging with
consensus DNH ratings (Table 1). Nineteen (53%) of
Figure 1. (A and B) Example SWI images at the level of the substantia nigra from a control participant (A) and a patient with Parkinson’s disease
(B). The dorsal nigral hyperintensity can be seen in the control participant (red arrows), but is absent in the patient with Parkinson’s disease. (C
and D) images used in quantification of the DNH signal. (C) A template image showing the average normalized SWI intensity across 32 healthy
control subjects. (D) regions of interest from the left (blue) and right (red) DNH were used to calculate the mean DNH signal intensity in each
participant. Abbreviations: SWI, susceptibility-weighted imaging; DNH, dorsal nigral hyperintensity.
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these patients had normal DaT SPECT/CT imaging as
rated by the blinded radiologist, while 14 (39%) had
abnormal imaging and three (8%) were classed as border-
line. The results of the SWI DNH assessments according
to these categorical DaT SPECT/CT outcomes are shown
in Table 5. There was good agreement between imaging
modalities for the 19 RBD patients with normal
dopaminergic imaging: 17 (89%) of these individuals had
retained the presence of the DNH. There was less concor-
dance in the 14 RBD patients with abnormal dopaminer-
gic imaging: six (43%) of these patients had DNH
present, while eight (57%) had loss of the DNH. One of
the three RBD patients with borderline dopaminergic
imaging had loss of the DNH and the other two had
DNH present.
Figure 2 shows DaT SPECT/CT ratios extracted from
the putamen (mean of left and right) of RBD patients
grouped according to the presence or absence of DNH on
SWI imaging. Those with absence of the DNH had signif-
icantly lower DaT SPECT/CT signal in the putamen com-
pared to those with the DNH present (mean putamen
uptake ratios 1.89 vs. 2.33, P = 0.002).
In the seven RBD patients with unilateral loss of the
DNH, dopaminergic signal in the putamen ipsilateral to
the DNH loss was significantly lower than in the con-
tralateral putamen (mean putamen ratios 1.72 ipsilateral
vs. 1.87 contralateral, P = 0.01).
Quantification of DNH signal intensity
The normalized mean intensity values extracted from the
region of the DNH are shown in Figure 3, grouped
according to patient category and excluding only the eight
subjects with artifact-degraded images (N.B. the five sub-
jects with inter-rater discordance and the one subject with
nondiagnostic imaging by visual rating are included).
Table 1. Breakdown of the number of subjects included at each stage of the analysis.
Controls PD patients All RBD patients
RBD with parallel
DaT SPECT/CT imaging
(A) Number of subjects imaged with SWI 32 27 46 42
(B) Number of subjects excluding those
with motion-degraded SWI images
(subjects included in automated
DNH quantification)
30 25 42 38
(C) Number of subjects with diagnostic
imaging and consensus visual DNH
ratings (subjects included in visual
DNH outcome analysis)
26 25 40 36
Abbreviations: SWI, susceptibility-weighted imaging; PD, Parkinson’s disease; RBD, rapid eye movement sleep behaviour disorder; DaT SPECT/CT,
Dopamine transporter single-photon emission computed tomography with computed tomography-based attenuation correction; DNH, dorsal
nigral hyperintensity.
Table 2. Baseline demographic and clinical variables.
Controls RBD patients PD patients
P-valueN = 30 N = 42 N = 25
Age, years, mean (SD) 69.1 (8.15) 64.8 (8.03) 64.8 (10.12) Con vs RBD: 0.03
Con vs PD: 0.08
RBD vs PD: 0.97
Sex (% male) 80% 98% 60% Con vs RBD: 0.01
Con vs PD: 0.10
RBD vs PD: <0.001
Disease duration, years, mean (SD)1 n/a 2.5 (2.44) 5.2 (2.31) n/a
UPDRS III score, mean (SD) 2.7 (2.07) 5.6 (3.68) 31.9 (14.28) Con vs RBD: <0.001
Con vs PD: <0.001
RBD vs PD: <0.001
Abbreviations: RBD, rapid eye movement sleep behaviour disorder; PD, Parkinson’s disease; Con, controls; UPDRS, Unified Parkinson’s Disease
Rating Scale.
1For RBD patients, time since RBD diagnosis by polysomnography; for PD patients, time since clinical diagnosis.
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Significant differences were observed between the means
in all three pairwise comparisons, with a stepwise decline
in signal intensity from controls to RBD patients and
from RBD patients to PD patients. In a receiver operating
characteristic (ROC) analysis, the mean intensity of the
DNH region separated PD patients from controls with an
area under the curve (AUC) of 0.86, with a cutoff value
of 0.823 giving an optimum combination of sensitivity
(84%) and specificity (80%). Among RBD patients, 19 of
42 (45%) had DNH signal intensity below this cutoff
level.
The mean DNH intensity did not correlate with
UPDRS III scores in either RBD patients (r = 0.15,
P = 0.33) or PD patients (r = 0.10, P = 0.65). There was
no significant difference in DNH intensity between RBD
patients with normal versus abnormal dopaminergic
imaging (0.836 vs. 0.826, P = 0.66), nor any direct corre-
lation between mean DNH intensity and mean DaT
SPECT/CT signal in the putamen (r = 0.24, P = 0.15).
Table 3. Results of binary visual assessments of the dorsal nigral hyperintensity.
Controls RBD patients PD patients
N = 26 N = 40 N = 25
Number with DNH present (% of patient group) 24 (92.3%) 29 (72.5%) 1 (4.0%)
Number with DNH absent (% of patient group) 2 (7.7%) 11 (27.5%) 24 (96.0%)
Abbreviations: RBD, rapid eye movement sleep behaviour disorder; PD, Parkinson’s disease; DNH, dorsal nigral hyperintensity.
Table 4. Clinical parkinsonian features compared in RBD patients according to the presence or absence of the dorsal nigral hyperintensity (DNH).
RBD DNH present RBD DNH absent
P valueN = 29 N = 11
MDS-UPDRS III 5.14 (3.57) 5.73 (3.74) 0.65
Purdue Pegboard score 32.1 (5.61) 34.0 (3.23) 0.30
Olfaction (Sniffin Sticks score) 8.2 (3.51) 6.6 (3.86) 0.25
Postural systolic blood pressure change (mm Hg) 7.7 (13.9) 1.4 (14.1) 0.24
MoCA score 25.4 (3.18) 26.0 (2.28) 0.57
Epworth sleepiness score 7.4 (4.35) 5.8 (5.69) 0.37
Beck depression inventory score 10.7 (9.73) 6.3 (4.59) 0.07
Anxiety score (HADS) 7.1 (4.64) 3.6 (3.93) 0.04
Apathy severity (LARS) 19.8 (7.52) 23.6 (4.57) 0.13
MDS prodromal PD probability, % 82.2 (19.6) 95.2 (9.19) 0.01
Abbreviations: MDS, Movement Disorders Society; UPDRS, Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment;
HADS, Hospital Anxiety and Depression Scale; LARS, Lille Apathy Rating Scale.
Table 5. Comparison of DNH assessments and DaT SPECT/CT out-
comes in RBD patients.
RBD patients DaT SPECT/CT DaT SPECT/CT DaT SPECT/CT
N = 36 Normal Abnormal Borderline
DNH present 17 6 2
DNH absent 2 8 1
Abbreviations: RBD, rapid eye movement sleep behaviour disorder;
DNH, dorsal nigral hyperintensity; DaT SPECT/CT, dopamine trans-
porter single-photon emission computed tomography with CT attenu-
ation correction.
Figure 2. Dopaminergic SPECT/CT signal from the putamen in RBD
patients, grouped according to the presence or absence of dorsal
nigral hyperintensity on SWI imaging. RBD patients with loss of DNH
had significantly lower dopaminergic signal than those with DNH
present. Abbreviations: SWI, susceptibility-weighted imaging; DNH,
dorsal nigral hyperintensity; RBD, rapid eye movement sleep behavior
disorder; SPECT/CT, single-photon emission computed tomography
with CT attenuation correction.
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Discussion
Our study demonstrates that around a quarter of patients
with idiopathic RBD have loss of the dorsal nigral hyper-
intensity (DNH) on SWI imaging, a pattern of abnormal-
ity that occurs in established Parkinson’s disease and
indicates degeneration affecting nigrosome 1. Postmortem
studies have shown dopaminergic neuronal loss in PD to
be highest in nigrosome 1 compared to other substantia
nigra regions, with a maximal 98% loss seen.17 A subse-
quent pathoanatomical correlation using in vivo 7T MRI
confirmed that the loss of imaging hyperintensity seen in
nigrosome 1 corresponds to the loss of neuromelanin-
containing cells seen in PD patients.6 Our study therefore
provides important in vivo evidence of prodromal disease
in the substantia nigra and raises the possibility that SWI
may be of value in the risk stratification in RBD patients.
The observation that RBD patients with loss of the DNH
have reduced dopamine transporter binding in the puta-
men compared to those with the DNH present is impor-
tant evidence that this SWI sign is indicative of
nigrostriatal integrity. This is supported by the finding of
a higher probability of prodromal PD, calculated using
the MDS research criteria, in patients with DNH loss.
Our data add to a growing body of neuroimaging evi-
dence from populations at risk of Parkinsonian disorders
indicating that degeneration-related changes are detectible
early in the disease process.18 Loss of the dorsal nigral
hyperintensity has also been reported in asymptomatic
LRRK2 mutation carriers, suggesting that this marker
may be applicable to preclinical and prodromal disease
beyond those with RBD.19 The finding that nigral R2*
values in LRRK2 carriers are increased relative to controls
supports the idea that iron deposition may be the mecha-
nism underlying the imaging phenotype.20 Other MRI
modalities to have demonstrated disease-related changes
in the nigrostriatal system in RBD patients include neu-
romelanin-sensitive imaging21 and resting state functional
connectivity,22 while the evidence of dopaminergic dys-
function is now firmly established.23 Neuroimaging there-
fore holds great promise for the identification of
individuals who might benefit the most from targeted
neuroprotective interventions.
Comparison of our SWI outcomes with three smaller
studies that have previously investigated loss of the DNH
in RBD patients reveals some important differences: all
three studies reported higher rates of DNH loss than we
have observed, as well as a higher proportion of bilateral
abnormalities (Table 6).7–9 Methodological variations
including differences in imaging protocol, rating strategy
and rater experience may have influenced outcomes, and
it is possible that the effect of these is greater in RBD
patients than in controls or PD patients, where the pres-
ence of borderline cases may increase the ambiguity of
binary assessment.
However, it is also possible that our patients are on
average at an earlier prodromal stage. The long and vari-
able latency to phenoconversion in RBD patients means
that the small cohorts described previously could be easily
influenced by a few individuals who are near to conver-
sion. One study, for example, reported DNH absence in
11 of 18 RBD patients.9 However, they also observed con-
version to a neurodegenerative disorder in 5 of 18 RBD
patients (28%) after an average 18-month follow-up
Figure 3. Mean DNH signal intensities (reported as a proportion of
background intensity) calculated from SWI show a stepwise decline
across the three groups of participants. Pairwise comparisons show
significant differences between all three groups. Abbreviations: SWI,
susceptibility-weighted imaging; DNH, dorsal nigral hyperintensity.
Table 6. Rates of DNH absence in published RBD studies.
Study
Number of RBD patients
with adequate imaging
Mean age of RBD
patients, years
Mean RBD
duration, years
Proportion with absent
DNH on SWI
Proportion of abnormal
cases with unilateral
DNH absence
De Marzi et al., 20166 13 68.9 5.3 10/13 (77%) 1/10 (10%)
Frosini et al., 20177 16 69.3 6.3 9/16 (60%) 2/9 (22%)
Bae et al., 20188 18 70.5 5.9 11/18 (61%) 2/11 (18%)
This study 40 64.5 2.5 11/40 (28%) 7/11 (64%)
Abbreviations: RBD, rapid eye movement sleep behaviour disorder; SWI, susceptibility-weighted imaging; DNH, dorsal nigral hyperintensity.
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period. This is much higher than would be expected from
the overall average conversion rate of 6% per year in
RBD,24 and suggests that their RBD patients were at a rel-
atively advanced prodromal stage.
In the absence of longitudinal data, we cannot yet say
if our patients were at an earlier stage at the time of their
imaging; although they were younger and had a shorter
RBD disease duration than other studies, neither of these
are reliable indicators of prodromal staging.
If it were the case, however, that more advanced pro-
dromal cases had higher rates of DNH loss, it would sug-
gest that this marker could develop as patients progress
through the stage of prodromal disease after RBD diagno-
sis. Such sensitivity to disease progression would be an
important characteristic, and in contrast to substantia
nigra ultrasound, another binary risk marker, which does
not show change overtime.25
There was partial discrepancy in findings between the
dichotomised outcomes of SWI and DaT SPECT/CT in
our study. While we observed DNH loss in only 28% of
our RBD patients, the overall rate of DaT SPECT/CT
abnormality was higher at 39%, a figure broadly in line
with other studies indicating that 40–50% of RBD patients
have evidence of a dopaminergic deficit.26,27 Interestingly,
89% of those with normal dopaminergic imaging also had
normal SWI imaging, whereas only 57% of RBD patients
with a dopaminergic deficit had absence of the DNH.
One potential explanation for this would be that DNH
loss may occur at a later stage of nigrostriatal degenera-
tion than dopamine transporter deficit, again in keeping
with a relatively early stage of pathology in our cohort.
The retained presence of the DNH alongside abnormal
dopaminergic imaging would be consistent with the pro-
posed “dying-back” pattern of nigrostriatal axonal degen-
eration, in which synaptic dysfunction precedes loss of
the nigral cell bodies.28
The hypothesis that DNH loss is a later prodromal sign
than DaT abnormality remains to be tested by long-term
follow-up of the patients in this study. However, if this
was the case, it would have important implications for
the risk stratification of RBD patients, with perhaps
greater potential for the enrichment of near-term convert-
ers using SWI. This would be advantageous in the devel-
opment of prodromal cohorts for neuroprotective clinical
trials in which conversion to an overt synucleinopathy
were the primary outcome measure, and could rationalize
ionizing radiation use by targeting only those study par-
ticipants for DaT scan who have a high probability of a
change in dopaminergic transmission.
It is notable that the degree of discordance in outcomes
that we observed between SWI and DaT SPECT/CT is
greater than has been reported previously.8,9 This is
mainly due to the proportion of our RBD patients with
DNH present who had abnormal DaT SPECT/CT out-
comes. In contrast, the high positive predictive value of
DNH loss for DaT SPECT abnormality is a consistent
finding across all studies: when our data are combined
with these two previous studies, more than 90% of RBD
patients with loss of DNH have had abnormal dopamin-
ergic imaging.8,9 This makes DNH a potentially useful
stratification tool for clinical trial recruitment, where a
high positive predictive value for underlying disease
would be more important than a high sensitivity.
Despite the promise of nigral SWI as a biomarker, it
is limited in its observer rating system by a degree of
subjectivity, inter-rater discrepancy, and a binary out-
come measure that lacks quantification. Although this
method performs well enough to accurately discriminate
Parkinson’s patients from controls, a binary outcome
may be more problematic in prodromal patients where
there are expected to be many more borderline cases.
The simple method of signal quantification that we have
used in this study attempts to overcome some of these
limitations.
The overall pattern of results obtained using this
method matched that of the binary ratings, with a step-
wise decline in dorsal nigral intensity from controls to
RBD patients and from RBD patients to PD patients.
The objective DNH intensity measure performed well in
separating PD patients from controls and although this
discrimination was slightly less accurate than visual rat-
ings, importantly it included subjects with nondiagnostic
visual ratings. A possible explanation for this is that
automated signal quantification will not distinguish
between high signal from nigrosome 1 and high signal
caused by artifacts. Imperfect registration may also lead
to a limited amount of bright signal from outside the
nigra being included inadvertently in some cases. It is
possible, therefore, that a combination of visual assess-
ment and signal quantification would be required to
maximize accuracy.
As with the binary observer ratings, RBD patients were
more similar to controls than to PD patients, but signifi-
cantly different from both. Interestingly, when applying
the optimal DNH intensity cutoff from the PD versus
controls ROC analysis to RBD patients, a higher percent-
age was classified as abnormal (45%) than with the sub-
jective ratings (28%). It remains to be seen with
longitudinal follow-up whether objective SWI measure-
ments, and their change overtime, outperform binary rat-
ings in delineating disease stage. However, the
intermediate spread of values observed in RBD patients in
cross-sectional assessment suggests that the decline in
nigrosome 1 signal may be a gradual process.
The fact that we did not observe a correlation between
motor severity and DNH signal intensity may be accounted
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for by a floor effect in PD patients. The majority had bilat-
eral complete loss of the DNH and it is likely that the low
signal remaining in the dorsolateral nigra (Fig. 1B) is insen-
sitive to further change. In RBD patients this was also an
unsurprising finding, since motoric disease is largely
absent, UPDRS III scores are low, and no other nigrostri-
atal imaging modality has demonstrated any reproducible
correlation with UPDRS III scores in RBD patients.29
The fact that we did not observe any direct correlation
between the SWI and DaT SPECT/CT measurements sug-
gests that they describe distinct aspects of nigrostriatal
integrity. It is possible, therefore, that a combination of
the two modalities may be more informative than either
test alone. Further development of multimodal imaging
assessments will be an important avenue of future
research, including the combination of SWI with mea-
sures from other MRI sequences such as neuromelanin-
sensitive and diffusion-weighted MRI.21 Quick and objec-
tive means of signal quantification will be crucial in such
large multimodal models.
The large number of patients with polysomnographi-
cally proven RBD included in this study, as well as the
multimodal imaging approach and semiautomated SWI
analysis are major strengths. Nevertheless, we acknowl-
edge some important limitations. First, the three groups
are not precisely matched for age and sex, and
although previous studies have shown that age and sex
do not significantly affect binary assessments of the
DNH,10,11 we cannot rule out an element of bias as a
result of incomplete matching. Second, ethical approval
restrictions prevented us from obtaining DaT SPECT/
CT data in our control participants. While this did not
affect the principal aim of comparing dopaminergic sig-
nal between RBD patients with and without DNH loss,
it did mean that our dichotomization of normal and
abnormal DaT SPECT/CT outcomes was not made with
reference to our control population. However, we
believe that the subjective evaluation by an experienced,
blinded, clinical radiologist is an equally valid method
of assessment.
In conclusion, SWI imaging of the DNH is a promising
biomarker of prodromal neurodegeneration in RBD
patients, who exhibit an intermediate rate of abnormality
between PD patients and healthy controls. RBD patients
with loss of DNH have higher rates of dopaminergic defi-
cits compared to those without, and consequently may be
at higher risk of developing a Parkinsonian disorder in
the near-term. This finding suggests that SWI may be a
viable tool with which to enrich prodromal cohorts for
neuroprotective trials. Longitudinal assessments will
determine the predictive value of SWI imaging as well as
the ability of DNH quantification to detect meaningful
nigral degeneration overtime.
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Figure S1. The region of interest marked in red was used
to define the background brainstem signal intensity in
each subject in order to normalize the signal intensities
extracted from the substantia nigra.
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